drugset / Trial / NCT01031498
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
RandomizedParallel-groupOpen-labelSupportive care
Summary
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Timeline
- Start
- 2005-09
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ondansetron | Other / unclassified | 24 mg | Intravenous |
| Subject | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |